Identification

Name
Platelet Activating Factor
Accession Number
DB02261  (EXPT02559)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
  • Blood platelet-activating factor
  • PAF
  • PAF 16
  • PAF acether
  • Platelet-activating factor
Categories
UNII
42EWD89I80
CAS number
74389-68-7
Weight
Average: 523.6832
Monoisotopic: 523.363789599
Chemical Formula
C26H54NO7P
InChI Key
HVAUUPRFYPCOCA-AREMUKBSSA-N
InChI
InChI=1S/C26H54NO7P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21-31-23-26(34-25(2)28)24-33-35(29,30)32-22-20-27(3,4)5/h26H,6-24H2,1-5H3/t26-/m1/s1
IUPAC Name
(2-{[(2R)-2-(acetyloxy)-3-(hexadecyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium
SMILES
CCCCCCCCCCCCCCCCOC[C@H](CO[P@@]([O-])(=O)OCC[N+](C)(C)C)OC(C)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UGanglioside GM2 activatorNot AvailableHuman
UPlatelet-activating factor receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Platelet Activating Factor.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Platelet Activating Factor.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
AceclofenacAceclofenac may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
AcemetacinThe therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Acepromazine.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Platelet Activating Factor.Approved
AcetohexamidePlatelet Activating Factor may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Platelet Activating Factor is combined with Acetylcholine.Approved
AcetyldigitoxinPlatelet Activating Factor may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinPlatelet Activating Factor may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Platelet Activating Factor.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Platelet Activating Factor.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Experimental, Investigational
AlaproclateThe serum concentration of Platelet Activating Factor can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Withdrawn
AlfentanilAlfentanil may increase the bradycardic activities of Platelet Activating Factor.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Platelet Activating Factor.Approved, Vet Approved
AliskirenPlatelet Activating Factor may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Platelet Activating Factor.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Platelet Activating Factor.Approved
AmbrisentanPlatelet Activating Factor may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostinePlatelet Activating Factor may increase the hypotensive activities of Amifostine.Approved, Investigational
AmiodaroneThe therapeutic efficacy of Platelet Activating Factor can be increased when used in combination with Amiodarone.Approved, Investigational
AmitrazAmitraz may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Vet Approved
AmitriptylinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Amitriptyline.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Platelet Activating Factor.Approved
AmobarbitalThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Platelet Activating Factor can be decreased when combined with Amodiaquine.Approved, Investigational
AmoxapinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Amoxapine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Platelet Activating Factor.Approved, Illicit, Investigational
AndrographolideAndrographolide may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
ApocyninApocynin may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Platelet Activating Factor is combined with Arecoline.Experimental
AripiprazolePlatelet Activating Factor may increase the orthostatic hypotensive activities of Aripiprazole.Approved, Investigational
AsenapinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Asenapine.Approved
AtenololAtenolol may increase the hypotensive activities of Platelet Activating Factor.Approved
AvanafilAvanafil may increase the antihypertensive activities of Platelet Activating Factor.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Platelet Activating Factor.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Platelet Activating Factor.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
BarbexacloneThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Barbital.Illicit
BarnidipinePlatelet Activating Factor may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Platelet Activating Factor.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Platelet Activating Factor.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Platelet Activating Factor.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Platelet Activating Factor.Approved
BepridilBepridil may increase the hypotensive activities of Platelet Activating Factor.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Platelet Activating Factor is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved
BevantololPlatelet Activating Factor may increase the orthostatic hypotensive activities of Bevantolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Platelet Activating Factor.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Platelet Activating Factor.Approved
BL-1020BL-1020 may increase the hypotensive activities of Platelet Activating Factor.Investigational
BosentanBosentan may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
BQ-123Platelet Activating Factor may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Platelet Activating Factor.Approved
BrexpiprazolePlatelet Activating Factor may increase the orthostatic hypotensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Platelet Activating Factor.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Platelet Activating Factor.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Platelet Activating Factor.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
BucindololPlatelet Activating Factor may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
BunazosinPlatelet Activating Factor may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Platelet Activating Factor.Approved, Investigational
BupranololPlatelet Activating Factor may increase the hypotensive activities of Bupranolol.Approved
CabergolinePlatelet Activating Factor may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
CafedrinePlatelet Activating Factor may increase the hypotensive activities of Cafedrine.Investigational
CandesartanPlatelet Activating Factor may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Platelet Activating Factor.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Platelet Activating Factor.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Platelet Activating Factor.Approved
CarbamoylcholineThe risk or severity of adverse effects can be increased when Platelet Activating Factor is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Platelet Activating Factor.Experimental, Investigational
CarbutamidePlatelet Activating Factor may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Platelet Activating Factor.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Platelet Activating Factor.Approved
CarvedilolPlatelet Activating Factor may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
CeliprololPlatelet Activating Factor may increase the hypotensive activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Platelet Activating Factor is combined with Cevimeline.Approved
ChloroquineThe metabolism of Platelet Activating Factor can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Platelet Activating Factor.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
ChlorpromazinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamidePlatelet Activating Factor may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Platelet Activating Factor.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Platelet Activating Factor.Approved
CicletaninePlatelet Activating Factor may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Platelet Activating Factor.Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved
ClonixinClonixin may decrease the antihypertensive activities of Platelet Activating Factor.Approved
CloranololPlatelet Activating Factor may increase the hypotensive activities of Cloranolol.Experimental
ClozapinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Clozapine.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Platelet Activating Factor.Vet Approved
CryptenamineCryptenamine may increase the hypotensive activities of Platelet Activating Factor.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
CyclopenthiazidePlatelet Activating Factor may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Platelet Activating Factor.Approved
CymarinPlatelet Activating Factor may increase the bradycardic activities of Cymarin.Experimental
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Platelet Activating Factor.Approved
DapiprazolePlatelet Activating Factor may increase the orthostatic hypotensive activities of Dapiprazole.Approved
DapoxetineThe serum concentration of Platelet Activating Factor can be increased when it is combined with Dapoxetine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Platelet Activating Factor.Approved
DelaprilPlatelet Activating Factor may increase the hypotensive activities of Delapril.Investigational
DemecariumDemecarium may increase the bradycardic activities of Platelet Activating Factor.Approved
DeserpidinePlatelet Activating Factor may increase the hypotensive activities of Deserpidine.Approved
DeslanosidePlatelet Activating Factor may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Platelet Activating Factor can be increased when it is combined with Desvenlafaxine.Approved, Investigational
DetomidineDetomidine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Vet Approved
DextroamphetaminePlatelet Activating Factor may increase the orthostatic hypotensive activities of Dextroamphetamine.Approved, Illicit
DiazoxideDiazoxide may increase the hypotensive activities of Platelet Activating Factor.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Platelet Activating Factor.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Vet Approved
DiethylnorsperminePlatelet Activating Factor may increase the hypotensive activities of Diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
DigitoxinPlatelet Activating Factor may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinPlatelet Activating Factor may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Platelet Activating Factor may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Platelet Activating Factor.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Platelet Activating Factor.Approved
DistigmineDistigmine may increase the bradycardic activities of Platelet Activating Factor.Experimental
DL-MethylephedrineDL-Methylephedrine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved
DonepezilDonepezil may increase the bradycardic activities of Platelet Activating Factor.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Platelet Activating Factor.Approved
DoxazosinPlatelet Activating Factor may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinPlatelet Activating Factor may increase the orthostatic hypotensive activities of Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
DronedaroneDronedarone may increase the bradycardic activities of Platelet Activating Factor.Approved
DroperidolPlatelet Activating Factor may increase the orthostatic hypotensive activities of Droperidol.Approved, Vet Approved
DroxicamDroxicam may decrease the antihypertensive activities of Platelet Activating Factor.Withdrawn
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Investigational
DuloxetineThe serum concentration of Platelet Activating Factor can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Platelet Activating Factor.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Platelet Activating Factor.Approved
EfonidipinePlatelet Activating Factor may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Platelet Activating Factor.Approved, Vet Approved
EnalaprilatPlatelet Activating Factor may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
EpanololPlatelet Activating Factor may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Platelet Activating Factor is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Platelet Activating Factor.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Platelet Activating Factor.Approved
EprosartanEprosartan may increase the hypotensive activities of Platelet Activating Factor.Approved
Ergoloid mesylatePlatelet Activating Factor may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovinePlatelet Activating Factor may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved
EscitalopramPlatelet Activating Factor may increase the orthostatic hypotensive activities of Escitalopram.Approved, Investigational
EtanerceptEtanercept may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved
EtoperidoneThe serum concentration of Platelet Activating Factor can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Platelet Activating Factor.Investigational, Nutraceutical
ExisulindExisulind may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
FelodipineFelodipine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Platelet Activating Factor.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Platelet Activating Factor.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Platelet Activating Factor.Approved
FentanylFentanyl may increase the bradycardic activities of Platelet Activating Factor.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Platelet Activating Factor.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
Ferulic acidPlatelet Activating Factor may increase the hypotensive activities of Ferulic acid.Experimental
FingolimodPlatelet Activating Factor may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Platelet Activating Factor is combined with Floctafenine.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Platelet Activating Factor.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
FluoxetineThe serum concentration of Platelet Activating Factor can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolPlatelet Activating Factor may increase the orthostatic hypotensive activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may increase the hypotensive activities of Platelet Activating Factor.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Platelet Activating Factor.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Platelet Activating Factor.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Platelet Activating Factor.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Platelet Activating Factor.Approved, Investigational, Nutraceutical
GitoformatePlatelet Activating Factor may increase the bradycardic activities of Gitoformate.Experimental
GlibornuridePlatelet Activating Factor may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazidePlatelet Activating Factor may increase the hypoglycemic activities of Gliclazide.Approved
GlimepiridePlatelet Activating Factor may increase the hypoglycemic activities of Glimepiride.Approved
GlipizidePlatelet Activating Factor may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidonePlatelet Activating Factor may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepidePlatelet Activating Factor may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburidePlatelet Activating Factor may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Platelet Activating Factor is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Platelet Activating Factor.Approved
GuanazodinePlatelet Activating Factor may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Platelet Activating Factor.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Investigational
GuanoclorPlatelet Activating Factor may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzPlatelet Activating Factor may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanPlatelet Activating Factor may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Platelet Activating Factor.Experimental
HexamethoniumPlatelet Activating Factor may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Platelet Activating Factor.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Platelet Activating Factor.Experimental
HydralazineHydralazine may increase the hypotensive activities of Platelet Activating Factor.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Platelet Activating Factor.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
HydroxychloroquineThe metabolism of Platelet Activating Factor can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Platelet Activating Factor.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Platelet Activating Factor.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
IloperidonePlatelet Activating Factor may increase the orthostatic hypotensive activities of Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
ImidaprilPlatelet Activating Factor may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
ImipraminePlatelet Activating Factor may increase the orthostatic hypotensive activities of Imipramine.Approved
IndalpineThe serum concentration of Platelet Activating Factor can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Platelet Activating Factor.Approved
IndenololPlatelet Activating Factor may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Platelet Activating Factor.Withdrawn
IndoraminPlatelet Activating Factor may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanPlatelet Activating Factor may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkPlatelet Activating Factor may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Platelet Activating Factor.Experimental
IproclozideIproclozide may increase the hypotensive activities of Platelet Activating Factor.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Platelet Activating Factor.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Platelet Activating Factor.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Platelet Activating Factor.Approved, Investigational, Withdrawn
IsoxicamIsoxicam may decrease the antihypertensive activities of Platelet Activating Factor.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
KebuzoneKebuzone may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
KetanserinKetanserin may increase the hypotensive activities of Platelet Activating Factor.Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Platelet Activating Factor.Approved
LabetalolPlatelet Activating Factor may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipinePlatelet Activating Factor may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanatoside CPlatelet Activating Factor may increase the bradycardic activities of Lanatoside C.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Platelet Activating Factor.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
LevomilnacipranThe serum concentration of Platelet Activating Factor can be increased when it is combined with Levomilnacipran.Approved, Investigational
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Platelet Activating Factor.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Platelet Activating Factor.Approved
LinsidominePlatelet Activating Factor may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetaminePlatelet Activating Factor may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
LobelineThe risk or severity of adverse effects can be increased when Platelet Activating Factor is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Platelet Activating Factor.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
MacitentanPlatelet Activating Factor may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Platelet Activating Factor.Approved
MalathionMalathion may increase the bradycardic activities of Platelet Activating Factor.Approved, Investigational
ManidipinePlatelet Activating Factor may increase the hypotensive activities of Manidipine.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Platelet Activating Factor.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Vet Approved
MedetomidineMedetomidine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Platelet Activating Factor.Approved
MefloquineMefloquine may increase the bradycardic activities of Platelet Activating Factor.Approved, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Platelet Activating Factor.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Platelet Activating Factor.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Platelet Activating Factor.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
MetahexamidePlatelet Activating Factor may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational, Withdrawn
MethacholinePlatelet Activating Factor may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Platelet Activating Factor.Investigational
MethohexitalThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Methohexital.Approved
MethoserpidinePlatelet Activating Factor may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved, Investigational
MethyldopaMethyldopa may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
MethylergometrinePlatelet Activating Factor may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
MethylphenobarbitalThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinPlatelet Activating Factor may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololMetipranolol may increase the hypotensive activities of Platelet Activating Factor.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Platelet Activating Factor.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Platelet Activating Factor.Approved
MetoprololMetoprolol may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
MetyrosinePlatelet Activating Factor may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Platelet Activating Factor.Investigational, Withdrawn
MidodrinePlatelet Activating Factor may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Platelet Activating Factor can be increased when it is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the bradycardic activities of Platelet Activating Factor.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Platelet Activating Factor.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Platelet Activating Factor.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational, Withdrawn
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Investigational
MuzoliminePlatelet Activating Factor may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Platelet Activating Factor.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Platelet Activating Factor.Approved
NadololNadolol may increase the hypotensive activities of Platelet Activating Factor.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Platelet Activating Factor.Approved
NaftopidilPlatelet Activating Factor may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Vet Approved
NebivololPlatelet Activating Factor may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodonePlatelet Activating Factor may increase the orthostatic hypotensive activities of Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Platelet Activating Factor.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Platelet Activating Factor.Withdrawn
NicardipinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Nicardipine.Approved, Investigational
NicergolinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Nicergoline.Approved, Investigational
NicorandilPlatelet Activating Factor may increase the hypotensive activities of Nicorandil.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Platelet Activating Factor is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Platelet Activating Factor.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Platelet Activating Factor.Approved
NiguldipinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Niguldipine.Experimental
NilvadipinePlatelet Activating Factor may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Platelet Activating Factor.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved
NortriptylinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Nortriptyline.Approved
ObinutuzumabPlatelet Activating Factor may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Platelet Activating Factor.Withdrawn
OlanzapinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Olanzapine.Approved, Investigational
OleandrinPlatelet Activating Factor may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Platelet Activating Factor.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Platelet Activating Factor.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Platelet Activating Factor.Investigational
OrgoteinOrgotein may decrease the antihypertensive activities of Platelet Activating Factor.Vet Approved
OuabainPlatelet Activating Factor may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Platelet Activating Factor.Approved
OxprenololOxprenolol may increase the hypotensive activities of Platelet Activating Factor.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved
PalmidrolPalmidrol may decrease the antihypertensive activities of Platelet Activating Factor.Experimental, Nutraceutical
ParaoxonParaoxon may increase the bradycardic activities of Platelet Activating Factor.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Platelet Activating Factor.Approved
PargylinePargyline may increase the hypotensive activities of Platelet Activating Factor.Approved
ParoxetineThe serum concentration of Platelet Activating Factor can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
PenbutololPenbutolol may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
PentobarbitalThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Platelet Activating Factor.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Platelet Activating Factor.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Platelet Activating Factor.Approved
PeruvosidePlatelet Activating Factor may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Platelet Activating Factor.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Platelet Activating Factor.Withdrawn
PhenobarbitalThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePlatelet Activating Factor may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Platelet Activating Factor.Withdrawn
PhentolaminePlatelet Activating Factor may increase the orthostatic hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Platelet Activating Factor.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Platelet Activating Factor is combined with Pilocarpine.Approved, Investigational
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Platelet Activating Factor.Approved
PindololPindolol may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Platelet Activating Factor.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Platelet Activating Factor.Withdrawn
PizotifenPlatelet Activating Factor may increase the orthostatic hypotensive activities of Pizotifen.Approved
PolythiazidePolythiazide may increase the hypotensive activities of Platelet Activating Factor.Approved
PranoprofenPranoprofen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental, Investigational
PrazosinPlatelet Activating Factor may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Platelet Activating Factor can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineProcaine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Platelet Activating Factor.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PromazinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
PropafenoneThe serum concentration of Platelet Activating Factor can be increased when it is combined with Propafenone.Approved
PropericiazinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
PropiomazinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Propiomazine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Platelet Activating Factor.Vet Approved
PropiverinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Propiverine.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
ProscillaridinPlatelet Activating Factor may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved
PTC299PTC299 may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Platelet Activating Factor.Approved, Investigational
QuetiapinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
QuinidinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Quinidine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Platelet Activating Factor.Approved
RacepinephrineRacepinephrine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved
RamiprilRamipril may increase the hypotensive activities of Platelet Activating Factor.Approved
RasagilineRasagiline may increase the hypotensive activities of Platelet Activating Factor.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Platelet Activating Factor.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Platelet Activating Factor.Approved
RemikirenRemikiren may increase the hypotensive activities of Platelet Activating Factor.Approved
RescinnaminePlatelet Activating Factor may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Experimental, Investigational
RifampicinThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
RiociguatPlatelet Activating Factor may increase the hypotensive activities of Riociguat.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Investigational
RituximabPlatelet Activating Factor may increase the hypotensive activities of Rituximab.Approved
RivastigminePlatelet Activating Factor may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational, Withdrawn
RomifidineRomifidine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Vet Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Platelet Activating Factor.Withdrawn
SalicylamideSalicylamide may decrease the antihypertensive activities of Platelet Activating Factor.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Platelet Activating Factor.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Platelet Activating Factor.Experimental
SecobarbitalThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational, Vet Approved
SelexipagPlatelet Activating Factor may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Platelet Activating Factor.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
SertralineThe serum concentration of Platelet Activating Factor can be increased when it is combined with Sertraline.Approved
SildenafilSildenafil may increase the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
SilodosinPlatelet Activating Factor may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanPlatelet Activating Factor may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Platelet Activating Factor.Approved
SpiraprilSpirapril may increase the hypotensive activities of Platelet Activating Factor.Approved
SRT501SRT501 may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
SufentanilSufentanil may increase the bradycardic activities of Platelet Activating Factor.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Platelet Activating Factor.Approved
SulindacSulindac may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
TacrineTacrine may increase the bradycardic activities of Platelet Activating Factor.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
TafenoquineThe metabolism of Platelet Activating Factor can be decreased when combined with Tafenoquine.Investigational
TalinololPlatelet Activating Factor may increase the hypotensive activities of Talinolol.Investigational
TamsulosinPlatelet Activating Factor may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
TemocaprilPlatelet Activating Factor may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Platelet Activating Factor.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Platelet Activating Factor.Vet Approved
TerazosinPlatelet Activating Factor may increase the orthostatic hypotensive activities of Terazosin.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Platelet Activating Factor.Approved
TerlipressinPlatelet Activating Factor may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatinePlatelet Activating Factor may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalinePlatelet Activating Factor may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the antihypertensive activities of Platelet Activating Factor.Approved
ThiamylalThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Platelet Activating Factor.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Platelet Activating Factor.Withdrawn
ThiopentalThe serum concentration of Platelet Activating Factor can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Thioproperazine.Approved
ThioridazinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Thioridazine.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Platelet Activating Factor.Approved
TibolonePlatelet Activating Factor may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenPlatelet Activating Factor may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Platelet Activating Factor.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Investigational
TolazamidePlatelet Activating Factor may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamidePlatelet Activating Factor may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Platelet Activating Factor.Approved
TolonidinePlatelet Activating Factor may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Platelet Activating Factor.Approved
TorasemideTorasemide may increase the hypotensive activities of Platelet Activating Factor.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Platelet Activating Factor.Approved
TranilastTranilast may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Platelet Activating Factor.Approved
TrazodonePlatelet Activating Factor may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
TribenosideTribenoside may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Platelet Activating Factor.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Platelet Activating Factor.Approved, Vet Approved
TrifluoperazinePlatelet Activating Factor may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
TriflupromazineTriflupromazine may increase the hypotensive activities of Platelet Activating Factor.Approved, Vet Approved
TrimazosinPlatelet Activating Factor may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
TrimipraminePlatelet Activating Factor may increase the orthostatic hypotensive activities of Trimipramine.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Platelet Activating Factor.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Platelet Activating Factor.Approved
TyrothricinTyrothricin may increase the bradycardic activities of Platelet Activating Factor.Approved
UdenafilUdenafil may increase the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
UnoprostonePlatelet Activating Factor may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilPlatelet Activating Factor may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Platelet Activating Factor.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Platelet Activating Factor.Approved
VareniclineThe risk or severity of adverse effects can be increased when Platelet Activating Factor is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Platelet Activating Factor can be increased when it is combined with Venlafaxine.Approved
VerapamilPlatelet Activating Factor may increase the orthostatic hypotensive activities of Verapamil.Approved
VincaminePlatelet Activating Factor may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Platelet Activating Factor.Approved, Investigational
VinpocetinePlatelet Activating Factor may increase the hypotensive activities of Vinpocetine.Investigational
XipamidePlatelet Activating Factor may increase the hypotensive activities of Xipamide.Experimental
XylazineXylazine may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Platelet Activating Factor.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Platelet Activating Factor can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidonePlatelet Activating Factor may increase the orthostatic hypotensive activities of Ziprasidone.Approved
ZofenoprilPlatelet Activating Factor may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Platelet Activating Factor.Withdrawn
ZuclopenthixolPlatelet Activating Factor may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Aiya Sato, Michihiro Sugano, Kouhei Furuya, Takeshi Oshima, Harumitsu Kuwano, Tadashi Hata, Hideyuki Haruyama, "Platelet activating factor antagonists, named "the phomactins", their preparation and use." U.S. Patent US5308867, issued October, 1980.

US5308867
General References
Not Available
External Links
Human Metabolome Database
HMDB0062195
PubChem Compound
108156
PubChem Substance
46508665
ChemSpider
97241
BindingDB
85035
ChEBI
44811
ChEMBL
CHEMBL1235246
IUPHAR
1833
Guide to Pharmacology
GtP Drug Page
HET
PFS
PDB Entries
1tjj

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000225 mg/mLALOGPS
logP2.71ALOGPS
logP2.01ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)1.86ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area94.12 Å2ChemAxon
Rotatable Bond Count26ChemAxon
Refractivity151.67 m3·mol-1ChemAxon
Polarizability63.09 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9853
Blood Brain Barrier+0.8739
Caco-2 permeable-0.5288
P-glycoprotein substrateSubstrate0.5468
P-glycoprotein inhibitor INon-inhibitor0.708
P-glycoprotein inhibitor IINon-inhibitor0.8673
Renal organic cation transporterNon-inhibitor0.837
CYP450 2C9 substrateNon-substrate0.8951
CYP450 2D6 substrateNon-substrate0.8167
CYP450 3A4 substrateSubstrate0.5503
CYP450 1A2 substrateNon-inhibitor0.8835
CYP450 2C9 inhibitorNon-inhibitor0.895
CYP450 2D6 inhibitorNon-inhibitor0.9047
CYP450 2C19 inhibitorNon-inhibitor0.8362
CYP450 3A4 inhibitorNon-inhibitor0.7665
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9636
Ames testNon AMES toxic0.6905
CarcinogenicityCarcinogens 0.6219
BiodegradationReady biodegradable0.9563
Rat acute toxicity2.8285 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6381
hERG inhibition (predictor II)Non-inhibitor0.6618
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-1912020000-cd0b0948116f9c94f643

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1-alkyl,2-acetylglycero-3-phosphocholines. These are glycerophosphocholines that carry exactly one acetyl chain attached to the glycerol moiety through an ester linkage at the O2-position, and one alkyl chain attached through an ether linkage at the O1-position.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Glycerophospholipids
Sub Class
Glycerophosphocholines
Direct Parent
1-alkyl,2-acetylglycero-3-phosphocholines
Alternative Parents
Phosphocholines / Glycerol ethers / Dialkyl phosphates / Tetraalkylammonium salts / Carboxylic acid esters / Monocarboxylic acids and derivatives / Dialkyl ethers / Organopnictogen compounds / Organic salts / Organic oxides
show 3 more
Substituents
1-alkyl,2-acetylglycero-3-phosphocholine / Phosphocholine / Glycerol ether / Dialkyl phosphate / Organic phosphoric acid derivative / Phosphoric acid ester / Alkyl phosphate / Tetraalkylammonium salt / Quaternary ammonium salt / Carboxylic acid ester
show 15 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
2-acetyl-1-alkyl-sn-glycero-3-phosphocholine (CHEBI:44811) / 1-alkyl,2-acylglycerophosphocholines (LMGP01020046)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phospholipase activator activity
Specific Function
The large binding pocket can accommodate several single chain phospholipids and fatty acids, GM2A also exhibits some calcium-independent phospholipase activity (By similarity). Binds gangliosides a...
Gene Name
GM2A
Uniprot ID
P17900
Uniprot Name
Ganglioside GM2 activator
Molecular Weight
20838.1 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Platelet activating factor receptor activity
Specific Function
Receptor for platelet activating factor, a chemotactic phospholipid mediator that possesses potent inflammatory, smooth-muscle contractile and hypotensive activity. Seems to mediate its action via ...
Gene Name
PTAFR
Uniprot ID
P25105
Uniprot Name
Platelet-activating factor receptor
Molecular Weight
39203.075 Da
References
  1. Qian C, Hwang SB, Libertine-Garahan L, Eckman JB, Cai X, Scannell RT, Yeh CG: Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20. [PubMed:11529688]
  2. Pegorier S, Stengel D, Durand H, Croset M, Ninio E: Oxidized phospholipid: POVPC binds to platelet-activating-factor receptor on human macrophages. Implications in atherosclerosis. Atherosclerosis. 2006 Oct;188(2):433-43. Epub 2005 Dec 28. [PubMed:16386258]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747]

Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 17:45